Status: Recruiting
A Clinical Study on Neoadjuvant Treatment of Resectable Head and Neck Squamous Carcinoma With Immune-targeted Therapy and Lysogenic HSV Virus
Evaluation of the safety and tolerability of immune-targeted therapy combined with neoadjuvant therapy with lysogenic HSV virus for patients with surgically resectable squamous carcinoma of the head and neck.
Participants needed: 21
Trial details
Phase: Phase 1Age: 18-70Biological sex: AllType: InterventionalSponsor: West China HospitalUpdated: Dec 19, 2024Locations: 1
Eligibility criteria
Age ≥18 and ≤70 years old, regardless of gender; [+8]
Lymph node staging of N0 or Nx status; [+18]